Research Article

Natural Anthraquinones as Promising MAPK3 Inhibitors for Complementary Cancer Therapy

Table 3

Multiple modes of interactions between the catalytic site of MAPK3, top-ranked anthraquinones, and a positive control inhibitor.

Ligand nameHydrogen bond (distance A)Hydrophobic interaction (distance A)

(A) Anthraquinones
Emodin-8-glucoside (before MD)Asp184 (3.36); Glu88 (4.80); Asp123 (4.72, 4.21); Gln122 (4.15)Tyr53 (6.74, 6.49); Cys183 (6.15); Val56 (5.08); Lys71 (5.01)
Emodin-8-glucoside (after MD)Glu50 (4.34); Lys131 (4.87); Met125 (3.99, 5.0); Lys71 (4.46); Cys183 (3.54); Ser170 (3.51)Val56 (4.87); Leu173 (6.21); Cys183 (7.25)
Aloe emodin 8-glucosideAsp123 (4.72, 4.21, 4.47); Gln122 (4.28); Asp184 (3.57)Tyr53 (6.52); Cys183 (6.48); Val56 (4.68); Lys71 (5.33)
Pulmatin (chrysophanol-8-0-glucoside)Asp123 (4.67, 4.26); Gln122 (4.31); Asp184 (3.79)Tyr53 (6.57, 6.41); Val56 (4.39); Lys71 (5.03)
RhodoptilometrinAsp184 (4.09); Cys183 (4.66); Met125 (4.08); Leu124 (4.11); Gln122 (4.48)Lys71 (5.09); Cys183 (5.07); Ile48 (4.57); Ala69 (6.03); Val56 (5.01); Leu173 (5.42)
HypericinAsp128 (4.47); Glu50 (3.70)Tyr130 (6.71, 3.83); Tyr53 (5.73); Val56 (6.28)

Ulixertinib (before MD)Asn171 (3.61); ser170 (4.07); Asp128 (4.11, 4.32)Tyr53 (6.4)
Ulixertinib (after MD)Lys168 (4.36); Lys131 (4.95)Tyr130 (4.46); Lys168 (6.71)

MAPK3, mitogen-activated protein kinase-3.